2020 Net Revenues of $83.1 Million Increased 19% over 2019 Fourth Quarter Net Revenues of $24.7 Million or $80 Per Bottle New Sustained Release Pan-VEGF Inhibitor Pipeline Candidate Announced Today Conference Call and Webcast Today, February 25 th , at 5:00 p.m. ET DURHAM, N.C.
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 22, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 18, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
DURHAM, N.C. --(BUSINESS WIRE)--Jan. 11, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
